Prognostic factors in symptomatic Waldenstrom's macroglobulinemia

Giampaolo Merlini, Luca Baldini, Chiara Broglia, Mario Comelli, Maria Goldaniga, Giovanni Palladini, Giorgio Lambertenghi Deliliers, Paolo G. Gobbi

Research output: Contribution to journalArticlepeer-review


We analyze the prognostic value of the presenting features of a series of patients with symptomatic Waldenstrom's macroglobulinemia who were homogeneously treated. A total of 215 patients (119 males) with a median age of 62.6 years (range, 24.9 to 91.6) were retrospectively analyzed. The median overall follow-up was 57.6 months (range, 0.6 to 281): 58 (0.9 to 281) for living patients and 52.2 (0.6 to 261.3) for those who died. All patients were treated with alkylating agentbased chemotherapy. The overall median survival was 77.2 months, without significant differences based on the duration of the previous monoclonal gammopathy of undetermined significance (MGUS) phase. The multivariate Cox analysis performed on the whole population showed that age, hemoglobin level, and serum albumin level predicted survival. The addition β2microglobulin, available in the subgroup of 60 patients diagnosed after 1990, in a Cox stepwise selection showed that this parameter was by far the main prognostic determinant. Application of the Dhodapkar, Morel, and Gobbi scoring systems to this population of patients showed that all three stratified the population into groups with significantly distinct prognoses. A prognostic index based on age, hemoglobin, and albumin is capable of identifying various groups of patients with different therapeutic needs.

Original languageEnglish
Pages (from-to)211-215
Number of pages5
JournalSeminars in Oncology
Issue number2
Publication statusPublished - Apr 2003

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Prognostic factors in symptomatic Waldenstrom's macroglobulinemia'. Together they form a unique fingerprint.

Cite this